Table 4.
Adjusted multivariate analysis investigating the association between interventional telemonitoring (ITM) and all-cause of mortality compared to other study groups.
| ORa | 95% CI | P-value | |
|---|---|---|---|
| Age | 1.034 | (1.002–1.067) | 0.036 |
| Hypertension | 0.549 | (0.270–1.117) | 0.098 |
| Diabetes mellitus | 1.292 | (0.613–2.724) | 0.501 |
| Ischemic-HF | 0.894 | (0.453–1.763) | 0.746 |
| LVEF | 0.957 | (0.926–0.988) | 0.007 |
| Ivabradine use | 0.443 | (0.094–2.082) | 0.303 |
| (ACEi, ARB, ARNIs) | 0.452 | (0.212–0.962) | 0.039 |
| Ambulatory process | 0.968 | (0.248–3.773) | 0.963 |
| Groups | |||
| -STM-group | 1.250 | (0.584–2.675) | 0.565 |
| -ITM-group | 0.255 | (0.103–0.628) | 0.003 |
STM-group, standard telemonitoring-group; ITM-group, interventional telemonitoring group; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; ACEi, Angiotensin converting enzyme inhibitor; ARB: Angiotensinogen 2 receptor antagonist; ARNIs: Angiotensin receptor-neprilysin inhibitors; ORa, adjusted odds ratios.